Results 121 to 130 of about 18,962 (231)

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies

Diabetes, Obesity and Metabolism, EarlyView.
Rune Viig Overgaard, Henrik Agersø, Christian Hollensen, Naveen Rathor, Eric M. Bomberg   +4 more
wiley   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial. [PDF]

Stroke
Lu L, Yang B, Wang Y, Zhu C, Liu Z, Li F, Yang S, Liu Y, Yang Y, Liu X, Huang L, Xu A, Zhu H.   +12 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy. [PDF]

Ann Gastroenterol
Butt E, Yang J.
europepmc   +1 more source

The Effect of Behavioral Sleep Interventions on Measures of Obesity, Dietary Intake and Physical Activity in Adults With Poor Sleep Health: A Systematic Review, Meta‐Analysis and Meta‐Regression Analysis

Obesity Reviews, EarlyView.
ABSTRACT Background As poor sleep negatively impacts on adiposity, there is interest in examining whether improving sleep can improve adiposity markers. We reviewed studies aimed at improving sleep using (1) cognitive behavioral therapy for insomnia (CBT‐I) and/or sleep hygiene and (2) sleep extension on adiposity markers, dietary intake, and physical ...
Samiul A. Mostafa, Pushpa Singh, Feaz Babwah, Wasim Hanif, George Balanos, Krishnarajah Nirantharakumar, Jason G. Ellis, Abd A. Tahrani   +7 more
wiley   +1 more source

Methyl Proton Spin Relaxation (<i>R</i>₂/<i>R</i>₁) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs. [PDF]

Anal Chem
Lu J, Pang E, Chen K.
europepmc   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion. [PDF]

Int J Mol Sci
Hosseini A, M'Sadoques AJ, Stoicovy RA, Altsman VL, Raynshteyn L, Weinstein E, Baggio Lopez T, Del Calvo G, Leiker MG, Lymperopoulos A.   +9 more
europepmc   +1 more source